NEW YORK, Jan 5 - The U.S. Patent and Trade Office reaffirmed its broad policy of patenting genes Friday, issuing a set of guidelines that respond to a variety of concerns about the patentability of genetic information.

“DNA compounds having naturally occurring sequences are eligible for patenting when isolated from their natural state and purified and when the application meets the statutory criteria for patentability,” the guidelines said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.